Printer Friendly

Ciphergen announces protein expression profiling patent issuance.

Ciphergen Biosystems, Inc. (Fremont, CA; 510-505-2233) announced that the United States Patent and Trademark Office had issued United States Patent 6,225,047, directed to a novel protein expression profiling method for protein biomarker discovery. The method, invented at Ciphergen, called "Differential Retentate Chromatography," is an advanced form of SELDI (surface enhanced laser desorption/ionization) time-of-flight mass spectrometry. Differential Retentate Chromatography enables the discovery of multiple protein biomarkers useful in predictive medicine, including disease diagnosis, toxicology assessment, clinical trial stratification, and drug target identification and validation. The power of the method lies in its ability to provide high resolution fingerprinting of differentially expressed proteins in biological samples and rapidly validate the findings in a population study.

"We are delighted that the USPTO has acknowledged Differential Retentate Chromatography with a United States patent ," said William E. Rich, President and CEO of Ciphergen. "Clients of Ciphergen's Biomarker Discovery Centers and purchasers of our ProteinChip System are already using this powerful protein expression profiling method to discover and validate new protein biomarkers. This patent secures Ciphergen's exclusive right to the Differential Retentate Chromatography technology and, we believe, further enables our leadership in the field of clinical proteomics."

In the Differential Retentate Chromatography method of protein expression profiling, proteins from different biological samples are captured on a variety of chromatographic or affinity based biochip surfaces. The captured proteins are quantitatively detected directly "on-chip" by SELDI-time-of-flight mass spectrometry and compared in order to identify proteins that are present in different amounts in the samples. Proteins that are differentially present in two or more samples are candidate biomarkers for disease, toxicology or drug-responder status or may indicate pathway information.

"Many of Ciphergen's collaborators and customers, using this Differential Retentate Chromatography-based protein expression profiling method, have discovered multiple protein biomarkers in several different cancers, neurological disorders and other diseases," said Rich. "Further, several clinical studies have been recently reported at the American Association of Cancer Research meeting in New Orleans and published in the American Journal of Pathology showing that the use of multi-biomarkers in combination with advanced pattern recognition software can significantly increase the statistical confidence of a clinical diagnosis of disease. We believe that multi-biomarker strategies will yield significant advances in clinical diagnostics, including early detection of cancer. Ciphergen's future plans include marketing of clinical diagnostic systems and assays involving multi-biomarkers discovered using Differential Retentate Chromatography."

Ciphergen develops, manufactures and markets the ProteinChip System that enables protein discovery, characterization and assay development to provide researchers with a better understanding of biological functions at the protein level. The ProteinChip System is a novel, enabling tool in the emerging field of protein-based biology research, known as proteomics. Proteomics provides a direct approach to understanding the role of proteins in the biology of disease, monitoring of disease progression and the therapeutic effects of drugs. Ciphergen believes proteomics will be a major focus of biological research by enhancing the understanding of gene function and the molecular basis of disease.
COPYRIGHT 2001 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Ciphergen announces protein expression profiling patent issuance.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:May 1, 2001
Previous Article:Vical obtains angiogenesis patent.
Next Article:South Alabama Medical Science Foundation obtains United States patent.

Related Articles
Paradigm Genetics receives herbicide target patent.
Targeted Genetics' obtains adeno-associated virus patent.
Sangamo BioSciences granted patent covering methods for identifying target sequences.
Sangamo BioSciences granted zinc finger DNA-binding protein patent.
Vical granted key DNA vaccine patent in Europe.
Hybridon obtains patent for second generation antisense oligonucleotides.
Hybridon receives patent for orally administering second generation antisense oligonucleotides.
New patent adds to Hybridon's antisense chemistry patent portfolio.
Odyssey Thera granted United States patent for pathway-based drug discovery strategy.
Ciphergen licenses more than 25 patents from Health Discovery.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters